Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating sentiment.
The week’s news was headlined by the Food and Drug Administration issuing emergency use authorizations for two oral COVID-19 antiviral pills. Pfizer, Inc. (NYSE: PFE) received authorization for its oral drug Paxlovid on Wednesday, followed by Merck & Co., Inc.’s (NYSE: MRK) molnupiravir.
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) rallied strongly after it announced in-licensing of nano-sized COVID-19 antibody.
Here are the key biopharma …